Cryopreservation Breakthrough: Low-Dose Preconditioning Makes NK Cells "Fitter After Freezing"
Release time:
2026-10-23
NK cell (natural killer cell) therapy, with its distinctive advantages in anti-tumor treatment, is becoming a major direction in global cell-therapy R&D. Yet one long-standing bottleneck has persisted: NK cells are extremely sensitive to cryopreservation, and post-thaw viability and killing function drop markedly, severely limiting the clinical accessibility of "off-the-shelf" cell products. Recently, the NHC Key Laboratory of Cell Transplantation at Harbin Medical University, together with Northeast Agricultural University and other teams, published findings in Cell Death Discovery, an authoritative journal in the cell-death field — systematically dissecting the key mechanisms of freeze-thaw injury in NK cells and proposing intervention strategies to improve cryopreservation outcomes, adding another link to the advancement of cryobiological medicine.
From "freezable" to "well frozen": cryopreservation enters an era of refinement
The team compared three commonly used cryoprotective solutions (CryoStor CS10, ZKCELL FM-01, and an FBS+DMSO system) for NK cell cryopreservation. Results showed that albumin macromolecule-containing systems performed better in both short-term and 4-month mid-term storage: post-thaw viability, ATP levels, and killing activity against hematologic and solid tumor cells all exceeded those of the conventional system. This suggests that optimizing the composition of the cryoprotective matrix is an important route to improving cell cryopreservation quality, and offers reference value for building clinical-grade NK cell banks.
Naming the culprit: lysosomal damage is a key node in freeze-thaw injury
Using transmission electron microscopy, flow cytometry and Western blotting, the team found that post-thaw NK cells simultaneously displayed apoptosis, necroptosis, pyroptosis and other death modes, and that the damage kept worsening 4–12 hours after recovery — assays taken immediately upon thawing may therefore overestimate true cell quality. The study further confirmed that centrifugation after rewarming aggravates cell death in a speed-dependent manner, the core mechanism being impaired lysosomal membrane stability that lets cytotoxic contents leak out. The team recommends that post-thaw centrifugal force not exceed 300×g, and calls for new methods of cryoprotectant removal that require no centrifugation.
An innovative strategy: low-dose preconditioning "activates" cellular self-repair
Building on the principle that stress granules (SGs) can rapidly gather at sites of lysosomal damage and act as "molecular plugs" to patch membrane pores, the team applied brief low-dose LLOMe preconditioning to NK cells, successfully inducing stress granule formation and stabilizing the lysosomal membrane. This significantly improved post-thaw recovery and tumor-killing efficiency without impairing key effector functions such as degranulation. In animal experiments, NK cells cryopreserved under this strategy showed stronger tumor control and survival improvement in tumor-bearing mice.
The study forms a complete evidence chain from mechanistic dissection to intervention validation, indicating that cryopreservation is moving from an empirical craft toward precise design grounded in cell-death mechanisms. With optimization of cryoprotectant formulations, standardization of operating parameters and the development of novel preconditioning strategies, cryobiological technology will continue to provide solid support for immune cell therapy, cell bank construction and even regenerative medicine.
(Source: Liu Y, et al. Cell Death Discovery (2026) 12:286. DOI: 10.1038/s41420-026-03149-0)
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
